Oncology - European Medical Journal

This site is intended for healthcare professionals

Continue

Oncology

Filter
EMJ
10 Jul 2015

TATTON: Phase 1b trial of combination therapies with AZD9291 in EGFR-mutant lung cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses…
EMJ
26 Jun 2015

Follow up of the phase 3 RESPONSE trial of ruxolitinib in polycythemia vera

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris…
EMJ
26 Jun 2015

Phase 2 MMY2002 trial of daratumumab in myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, María-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca…
EMJ
26 Jun 2015

Results of the phase 3 ELOQUENT-2 trial

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA…
EMJ
26 Jun 2015

Results of the phase 3 PERSIST-1 trial of pacritinib for myelofibrosis

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris…
EMJ
26 Jun 2015

Results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab for multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of…
EMJ
26 Jun 2015

DNMT3A R882 mutations in AML promote chemoresistance and therapeutic relapse

Multivariate analysis of patients with acute myeloid leukaemia (AML) at day 28 in clinical or pathologic complete remission showed that DNMT3A R882…
EMJ
26 Jun 2015

Updated results from the SORAML trial of sorafenib in younger patients with newly diagnosed AML

The randomised, controlled phase 2 SORAML trial showed that the addition of the tyrosine kinase inhibitor, sorafenib, to chemotherapy improved event-free…
We’ve noticed you’re accessing
from North/South America.